Preventive treatment completion | Univariable | Multivariable | ||||
No | Yes# | OR (95% CI) | p-value | aOR (95% CI) | p-value | |
Total | 4097 | 23 634 (85) | ||||
Period | ||||||
1993–1996 | 718 | 4812 (87) | 0.77 (0.68–0.87) | <0.001 | 1.0 (0.86–1.2) | 0.84 |
1997–2000 | 1019 | 5080 (83) | 0.57 (0.51–0.64) | <0.001 | 0.77 (0.65–0.90) | 0.001 |
2001–2004 | 1075 | 4898 (82) | 0.52 (0.47–0.59) | <0.001 | 0.74 (0.63–0.87) | <0.001 |
2005–2008 | 776 | 4420 (85) | 0.66 (0.58–0.74) | <0.001 | 0.79 (0.67–0.92) | 0.002 |
2009–2013 | 509 | 4424 (90) | 1.0 | 1.0 | ||
Age group years | ||||||
0–14 | 222 | 2858 (93) | 1.0 | 1.0 | ||
15–24 | 1075 | 7471 (87) | 0.54 (0.46–0.63) | <0.001 | 0.53 (0.45–0.61) | <0.001 |
25–34 | 1068 | 5817 (84) | 0.42 (0.36–0.49) | <0.001 | 0.40 (0.35–0.47) | <0.001 |
35–44 | 927 | 4129 (82) | 0.35 (0.30–0.40) | <0.001 | 0.33 (0.28–0.39) | <0.001 |
45–54 | 630 | 2461 (80) | 0.30 (0.26–0.36) | <0.001 | 0.28 (0.24–0.33) | <0.001 |
55–64 | 143 | 717 (83) | 0.39 (0.31–0.49) | <0.001 | 0.30 (0.24–0.38) | <0.001 |
≥65 | 32 | 181 (85) | 0.44 (0.29–0.66) | <0.001 | 0.31 (0.20–0.47) | <0.001 |
Sex | ||||||
Male | 1956 | 11 634 (86) | 1.0 | 1.0 | ||
Female | 2139 | 11 981 (85) | 0.94 (0.88–1.0) | 0.07 | 0.93 (0.87–0.99) | 0.03 |
Origin | ||||||
Foreign born | 656 | 3817 (85) | 1.0 | 0.83 | 1.0 | |
Dutch born | 3408 | 19 646 (85) | 0.99 (0.90–1.1) | 0.81 | 1.2 (1.0–1.3) | 0.01 |
Unknown | 33 | 171 (84) | 0.89 (0.61–1.3) | 0.55 | 1.0 (0.70–1.5) | 0.84 |
Residence | ||||||
Urban | 981 | 5393 (85) | 1.0 | 1.0 | ||
Rural | 3116 | 18 241 (85) | 1.1 (0.99–1.2) | 0.11 | 1.1 (1.0–1.2) | 0.05 |
BCG vaccination | ||||||
No BCG | 3559 | 20 226 (85) | 1.0 | 0.04 | ||
BCG | 326 | 2162 (87) | 1.2 (1.0–1.3) | 0.01 | ||
Unknown | 212 | 1246 (85) | 1.0 (0.89–1.2) | 0.62 | ||
Diagnostic test | ||||||
TST | 894 | 5788 (87) | 1.0 | |||
IGRA | 54 | 368 (87) | 1.1 (0.78–1.4) | 0.73 | ||
TST and IGRA | 315 | 2582 (89) | 1.3 (1.1–1.5) | 0.001 | ||
Unknown | 2834 | 14 896 (84) | 0.81 (0.75–0.88) | <0.001 | ||
Target group | ||||||
TB contact | 2588 | 14 972 (85) | 1.0 | 1.0 | ||
Immunosuppression | 92 | 628 (87) | 1.2 (0.94–1.5) | 0.15 | 1.5 (1.2–1.9) | 0.001 |
Pre-exposure examination | 691 | 4140 (86) | 1.0 (0.95–1.1) | 0.45 | 1.0 (0.92–1.1) | 0.87 |
Professional at risk¶ | 36 | 348 (91) | 1.7 (1.2–2.4) | 0.004 | 1.6 (1.1–2.2) | 0.01 |
Traveller¶ | 41 | 511 (93) | 2.2 (1.6–3.0) | <0.001 | 1.79 (1.3–2.5) | <0.001 |
Other post-exposure | 641 | 2933 (82) | 0.79 (0.72–0.87) | <0.001 | 0.83 (0.75–0.92) | <0.001 |
Fibrotic lesions | 8 | 102 (93) | 2.2 (1.1–4.5 | 0.03 | 4.4 (2.1–9.2) | <0.001 |
Preventive treatment regimen | ||||||
6–9 months isoniazid | 3418 | 19 423 (85) | 1.0 | 1.0 | ||
4 months rifampicin | 65 | 667 (91) | 1.8 (1.4–2.3) | <0.001 | 1.7 (1.3–2.2) | <0.001 |
3–4 months rifampicin/isoniazid | 269 | 2896 (92) | 1.9 (1.7–2.2) | <0.001 | 1.7 (1.4–2.0) | <0.001 |
Other or unknown | 345 | 648 (65) | 0.33 (0.29–0.38) | <0.001 | 0.35 (0.30–0.40) | <0.001 |
Data are presented as n or n (%), unless otherwise stated. OR: odds ratio; aOR: adjusted OR; BCG: bacille Calmette–Guerin; TST: tuberculin skin test; IGRA: interferon-γ release assay; TB: tuberculosis. #: percentage completed of row total given in parentheses; ¶: post-exposure.